Chinook Therapeutics Inc Stock Price, News & Analysis

Chinook Therapeutics (Nasdaq: KDNY) presented significant findings on its BION-1301 and atrasentan programs at ASN Kidney Week 2021. BION-1301 demonstrated rapid and sustained proteinuria reduction of over 50% in patients with IgA nephropathy after three to six months of treatment. The drug was well-tolerated with no adverse events reported. Atrasentan showed a consistent pharmacokinetic profile across diverse populations. The company aims to refine dosing for BION-1301 as it progresses into later-stage trials.

Chinook Therapeutics, Inc. (NASDAQ: KDNY) announced its participation in ASN Kidney Week 2021, taking place from November 4-7, 2021. The company will present six abstracts on its BION-1301 and atrasentan clinical programs, focusing on IgA nephropathy treatment. Highlights include biomarker reductions and the correlation of endothelin activation with disease progression. An investor conference call will occur on November 4, 2021, at 4:30 PM EDT, featuring updates on the company's pipeline. More information can be found on Chinook's website.

Chinook Therapeutics (NASDAQ: KDNY) recently announced upcoming fireside chats at key investor conferences. The Oppenheimer Fall Healthcare Life Sciences & MedTech Summit is set for September 22 at 11:35 AM EDT, followed by the 2021 Cantor Virtual Global Healthcare Conference on September 28 at 2:40 PM EDT. Chinook will also engage in 1x1 meetings during these events. Investors can access live webcasts and recordings on Chinook's website for 90 days. The company specializes in developing precision medicines for kidney diseases, with lead programs targeting severe chronic kidney disorders.

Chinook Therapeutics, Inc. (NASDAQ: KDNY) announced participation in two upcoming virtual investor conferences. Management will engage in a live fireside chat at the Morgan Stanley 19th Annual Global Healthcare Conference on September 9 at 5:00 pm EDT. Additionally, there will be an on-demand fireside chat at the H.C. Wainwright 23rd Annual Global Investment Conference starting September 13 at 7:00 am EDT. The company will also hold 1x1 meetings between September 9 and 15. Archived webcasts will be available on their website for 90 days.

Chinook Therapeutics (Nasdaq: KDNY) reported a net loss of $42.6 million for Q2 2021, with total revenue slightly increasing due to a collaboration with Lilly. The company enrolled patients in its phase 2 AFFINITY trial and presented initial data for BION-1301 in IgA nephropathy, showing proof-of-concept. Cash and marketable securities totaled $229.8 million at the quarter's end. R&D expenses surged to $22.8 million, driven by clinical programs. Chinook expects to advance its pipeline with upcoming clinical trials and presentations slated for the second half of 2021.

Chinook Therapeutics (Nasdaq: KDNY) announced its participation in a virtual fireside chat at the William Blair Biotech Focus Conference on July 15, 2021, at 12:00 pm ET. Interested investors can access the live webcast and an archived recording on Chinook's website, available for 30 days. Chinook is focused on developing precision medicines for kidney diseases, with its lead program, atrasentan, in phase 3 trials for IgA nephropathy. The company is also advancing BION-1301 and CHK-336 for various kidney disorders, utilizing innovative research approaches.

Chinook Therapeutics (Nasdaq: KDNY) has announced the approval of a new employment inducement grant of stock options for a new employee, totaling 25,733 shares. The options have an exercise price of $14.12, equal to the closing price on June 30, 2021, and vest over four years. This grant follows Nasdaq Rule 5635(c)(4) and aims to attract talent to the company, which focuses on precision medicines for kidney diseases. Chinook is advancing its clinical programs, including atrasentan and BION-1301, targeting rare kidney disorders.

Chinook Therapeutics, Inc. (Nasdaq: KDNY) has announced significant promotions within its leadership team, appointing Tom Frohlich as Chief Operating Officer (COO) and Andrew King, D.V.M, Ph.D., as Chief Scientific Officer (CSO). Frohlich, co-founder and former Chief Business Officer, will manage key operational functions including business development and quality assurance. King, a prominent figure in kidney disease biology since joining Chinook in 2019, will lead discovery research. These promotions recognize their critical contributions toward establishing Chinook as a leader in precision medicines for kidney diseases.

Chinook Therapeutics (Nasdaq: KDNY) presented positive interim data for BION-1301 in a phase 1/2 study targeting IgA nephropathy (IgAN) at the 58th ERA-EDTA Congress. BION-1301 demonstrated good tolerability with no serious adverse events and significant reductions in 24-hour proteinuria, marking an initial proof-of-concept. The drug effectively lowered Gd-IgA1 levels and was successful in neutralizing APRIL, showcasing its potential as a disease-modifying therapy. An investor conference call is scheduled to discuss these findings further.